Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 2
2012 1
2014 1
2015 6
2016 4
2017 2
2018 6
2019 6
2020 6
2021 2
2022 4
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Results by year

Filters applied: . Clear all
Page 1
Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives.
Rebuzzi SE, Rescigno P, Catalano F, Mollica V, Vogl UM, Marandino L, Massari F, Pereira Mestre R, Zanardi E, Signori A, Buti S, Bauckneht M, Gillessen S, Banna GL, Fornarini G. Rebuzzi SE, et al. Among authors: zanardi e. Cancers (Basel). 2022 Feb 28;14(5):1245. doi: 10.3390/cancers14051245. Cancers (Basel). 2022. PMID: 35267553 Free PMC article. Review.
BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications.
Messina C, Cattrini C, Soldato D, Vallome G, Caffo O, Castro E, Olmos D, Boccardo F, Zanardi E. Messina C, et al. Among authors: zanardi e. J Oncol. 2020 Sep 7;2020:4986365. doi: 10.1155/2020/4986365. eCollection 2020. J Oncol. 2020. PMID: 32963528 Free PMC article. Review.
Treatment of elderly patients with metastatic renal cell carcinoma.
Zanardi E, Grassi P, Cavo A, Verzoni E, Maggi C, De Braud F, Boccardo F, Procopio G. Zanardi E, et al. Expert Rev Anticancer Ther. 2016;16(3):323-34. doi: 10.1586/14737140.2016.1131613. Epub 2016 Jan 20. Expert Rev Anticancer Ther. 2016. PMID: 26654225 Review.
Beyond the Prognostic Value of 2-[18F]FDG PET/CT in Prostate Cancer: A Case Series and Literature Review Focusing on the Diagnostic Value and Impact on Patient Management.
Borea R, Favero D, Miceli A, Donegani MI, Raffa S, Gandini A, Cremante M, Marini C, Sambuceti G, Zanardi E, Morbelli S, Fornarini G, Rebuzzi SE, Bauckneht M. Borea R, et al. Among authors: zanardi e. Diagnostics (Basel). 2022 Feb 24;12(3):581. doi: 10.3390/diagnostics12030581. Diagnostics (Basel). 2022. PMID: 35328134 Free PMC article. Review.
Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer.
Nuzzo PV, Pederzoli F, Saieva C, Zanardi E, Fotia G, Malgeri A, Rossetti S, Valenca Bueno L, Andrade LMQS, Patrikidou A, Mestre RP, Modesti M, Pignata S, Procopio G, Fornarini G, De Giorgi U, Russo A, Francini E; SPARTACUSS Investigators. Nuzzo PV, et al. Among authors: zanardi e. J Transl Med. 2023 Feb 3;21(1):75. doi: 10.1186/s12967-022-03861-2. J Transl Med. 2023. PMID: 36737752 Free PMC article.
47 results